| Popis: |
Medical therapy remains the most popular treatment for gastroesophageal reflux disease (GERD). While interest in drug development for GERD has declined over the past few years, primarily due to the conversion of most proton pump inhibitors (PPIs) to generic and over-the-counter compounds, there are still numerous areas of unmet needs in GERD. Drug development in GERD has been focused on potent histamine type 2 receptor antagonists (H2RAs), extended-release PPI’s, PPI combination, potassium-competitive acid blockers, transient lower esophageal sphincter relaxation (TLESR) reducers, prokinetics, mucosal protectants, and esophageal-specific pain modulators. It is likely that further innovation in therapeutic options for GERD will continue to decline in the next decade, and the aforementioned compounds will be niched for specific areas of unmet needs in GERD, rather than compete with the presently available anti-reflux therapies for GERD. |
